[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-505078-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-505078-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","long-term-use-of-urate-lowering-therapies-and-cognitive-decline-in-older-adults","Long-term Use of Urate-Lowering Therapies and Cognitive Decline in Older Adults","","Long-term use of urate-lowering therapies (ULT) may reduce inflammation during aging and help prevent cognitive decline. This study assessed the association between long-term ULT use and cognitive decline in community-dwelling adults aged 70+ with spontaneous memory complaints. A secondary observational analysis used Multidomain Alzheimer Preventive Trial (MAPT) data (n=1,673) over a 5-year follow-up, comparing ULT-treated (PT≥75, PT\u003C75) versus non-treated participants (PNT) using linear mixed models adjusted for baseline factors and intervention groups.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/long-term-use-of-urate-lowering-therapies-and-cognitive-decline-in-older-adults/505078/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/long-term-use-of-urate-lowering-therapies-and-cognitive-decline-in-older-adults/505078.png","ImageObject",300,407,{"name":42,"@type":43},"anakgang17","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-31","2026-10-04",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What question did the study investigate?","Question",{"text":63,"@type":64},"The study investigated whether long-term use of urate-lowering therapies (ULT) is associated with cognitive decline in community-dwelling older adults with subjective memory complaints over five years.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were participants grouped based on ULT use?",{"text":68,"@type":64},"Participants were grouped by ULT use during at least 75% of the study period (PT≥75), less than 75% (PT\u003C75), or non-treatment (PNT).",{"name":70,"@type":61,"acceptedAnswer":71},"What was the main finding after five years?",{"text":72,"@type":64},"After five years, only the non-treated group showed a significant decline in the cognitive composite score, while there were no significant between-group differences in change of the composite score; overall ULT use was not associated with reduced cognitive decline.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},505078,1791459243,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,109,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":107,"slug":108},7,40,"healthcare",{"id":110,"doc_module":4,"doc_module_name":25,"category_name":111,"show_sort_weight":112,"slug":113},8,"Research & Report",30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":106,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":4},962090883568,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","| |  |\n| --- | --- |\n| |  |\n|  􀂦 \u003Cbr>Centre Hospital ier Universitaire de Toulouse\u003Cbr>\u003Cbr>Centre Hospital ier Universitaire de Toulouse\u003Cbr>\u003Cbr>Centre Hospital ier Universitaire de Toulouse\u003Cbr>\u003Cbr>Centre Hospital ier Universitaire de Toulouse\u003Cbr>\u003Cbr>Centre Hospital ier Universitaire de Toulouse | |\n| \u003Cbr> allopurinol, Alzheimer’s disease, cognitive decline, composite cognitive score, dementia, febuxostat, gout, gouty arthritis, in§ammaging, monosodium urate crystal-induced arthritis, Multidomain Alzheimer Preventive Trial study, urate-lowering therapies\u003Cbr> March 1st, 2022\u003Cbr> [https://doi.org/10.21203/rs.3.rs-699328/v2](https://doi.org/10.21203/rs.3.rs-699328/v2)\u003Cbr> 􀁱 􀅏 This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License |  |\n\nLong-term use of urate-lowering therapies (ULT) may reduce in§ammaging and thus prevent cognitive decline during aging. This article examined the association between long-term use of ULT and cognitive decline among communitydwelling older adults with spontaneous memory complaints.  \nWe performed a secondary observational analysis using data of 1,673 participants ≥70 years old from the Multidomain Alzheimer Preventive Trial (MAPT Study), a randomized controlled trial assessing the effect of amultidomain intervention, the administration of polyunsaturated fatty acids (PUFA), both, or placebo on cognitive decline. We compared cognitive decline during the 5-year follow-up between three groups according to ULT use:  \nparticipants treated with ULT during at least 75% of the study period (PT≥75; n =51), less than 75%(PT\u003C75; n =31), and non-treated participants (PNT; n =1,591) . Cognitive function (measured by a composite score) was assessed at baseline, 6 months and every year for 5 years. Linear mixed models were performed and adjusted for age, sex, body mass index (BMI), diagnosis of arterial hypertension or diabetes, baseline composite cognitive score, and MAPT intervention groups.  \nAfter the 5-year follow-up, only non-treated participants presented a signi¦cant decline in the cognitive composite score (mean change-0 .173, 95%CI -0 .212 to-0 . 135; p\u003C0.0001) . However, there were no differences in change of the composite cognitive score between groups (adjusted between-group difference for PNT vs. PT\u003C75: 0.089, 95%CI -0.160 to 0.338, p = 0 .484; PNT vs. PT≥75: 0.174, 95%CI -0 .042 to 0.391, p = 0 .115) .  \nUse of ULT was not associated with reduced cognitive decline over a 5-year follow-up among community-dwelling older adults at risk of dementia.  \nCognitive decline is a rising issue as the population of older adults keeps increasing. Neuroin§ammation involving oxidative stress1 is reported to play a major role2 on cognitive impairment.  \nThe fact that uric acid has anti-oxidant properties and has the ability to reduce systemic in§ammation has raised the hypothesis that hyperuricemia or gout may be protective against dementia, Alzheimer’s disease (AD) and cognitive decline3,4. Recent epidemiological studies that investigated the association between serum uric acid level and AD were mainly cross-sectional and are somewhat con§icting5. However, it was also reported in a large cohort that gout was independently associated with a 15% higher risk of incident dementia among older adults6.  \nPublications have paradoxically reported that urate-lowering therapies (ULT) may decrease the systemic in§ammation and reduce the production of oxidative species7,8. ULT may also reverse endothelial dysfunction and thus have cardioprotective bene¦ts. Neuroprotective effects of ULT both in animal studies9 and human cohorts10 have been reported. Singh et al.11 reported a dose-related reduction in the risk of dementia among people older than 65 years treated with ULT.  \nThese studies remain scarce and controversial. Some of their limitations were the lack of evaluation criteria of cognitive decline12,13,14,15 and short-term follow-ups. Furthermore, analyses were based on gener","cbCaihbtVPxkBArV","https://ap.wps.com/l/cbCaihbtVPxkBArV","pdf",415501,14,"English","# Background and Rationale\n# Study Design and Methods\n# Results Over the 5-Year Follow-up\n# Discussion and Implications","[{\"question\":\"What question did the study investigate?\",\"answer\":\"The study investigated whether long-term use of urate-lowering therapies (ULT) is associated with cognitive decline in community-dwelling older adults with subjective memory complaints over five years.\"},{\"question\":\"How were participants grouped based on ULT use?\",\"answer\":\"Participants were grouped by ULT use during at least 75% of the study period (PT≥75), less than 75% (PT\\u003c75), or non-treatment (PNT).\"},{\"question\":\"What was the main finding after five years?\",\"answer\":\"After five years, only the non-treated group showed a significant decline in the cognitive composite score, while there were no significant between-group differences in change of the composite score; overall ULT use was not associated with reduced cognitive decline.\"}]","Long-term Use of Urate-Lowering Therapies and Cognitive Decline in Older Adults | PDF",1791088669,35]